• 1. Liver Transplantation Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, P. R. China;
  • 2. Clinical Center for Pediatric Liver Transplantation, National Clinical Research Center of Digestive Diseases, Capital Medical University, Beijing 100050, P. R. China;
ZHU Zhijun, Email: zhu-zhijun@outlook.com
Export PDF Favorites Scan Get Citation

Objective To observe the clinical effect of Rituximab combined with intravenous immunoglobulin (IVIG) in preventing blood group antibody mediated rejection (AMR) in pediatric ABO incompatible living donor liver transplantation (ABOi-LDLT).Methods A total of 503 cases of pediatric living donor liver transplantation in Beijing Friendship Hospital Affiliated to Capital Medical University from June 2013 to December 2020 were retrospectively collected; the overall survival of recipient and graft were compared between ABOi-LDLT and ABO compatible living donor liver transplantation (ABOc-LDLT), and we summarized the data of AMR in 7 cases received Rituximab+IVIG protocol.Results There were 53 cases of ABOi-LDLT and 450 cases of ABOc-LDLT in our study. The 5-year cumulative survival rate of recipients and grafts was 98.0% and 96.0% in the ABOi-LDLT group respectively, and in ABOc-LDLT group was 92.2% and 89.1% respectively, there was no significant difference between the two groups (P=0.232, P=0.381). Seven children with blood group antibody titer >1∶64 were included in the study. On the basis of classical intensive immunosuppressive therapy, all patients were treated with Rituximab+IVIG. The blood group antibody titer of 6 patients remained stable, and no rejection occurred; one patient developed severe AMR and graft failure, and recovered after salvage treatment of ABOc-LDLT.Conclusion Rituximab+IVIG can be used as an effective therapeutic option to prevent blood group AMR after ABOi-LDLT.

Citation: QU Wei, ZHU Zhijun, WEI Lin, SUN Liying, ZENG Zhigui, LIU Ying, WANG Jun, TAN Yule, ZHANG Jinping. Clinical research of effect of Rituximab+IVIG regimen to prevent pediatric ABO incompatible living donor liver transplantation. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2021, 28(8): 987-991. doi: 10.7507/1007-9424.202104027 Copy

  • Previous Article

    Surgical treatment of asphyxiating thoracic dysplasia (Jeune syndrome)
  • Next Article

    Influence of PD-1 monoclonal antibody on anti-lung cancer effect of cytokine-induced killer cells (CIK) induced and expanded in vitro